249 related articles for article (PubMed ID: 33746582)
1. Granzyme family acts as a predict biomarker in cutaneous melanoma and indicates more benefit from anti-PD-1 immunotherapy.
Wu X; Wang X; Zhao Y; Li K; Yu B; Zhang J
Int J Med Sci; 2021; 18(7):1657-1669. PubMed ID: 33746582
[TBL] [Abstract][Full Text] [Related]
2. Predicting the clinical outcome of melanoma using an immune-related gene pairs signature.
Meng L; He X; Zhang X; Zhang X; Wei Y; Wu B; Li W; Li J; Xiao Y
PLoS One; 2020; 15(10):e0240331. PubMed ID: 33031392
[TBL] [Abstract][Full Text] [Related]
3. Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study.
Wagner NB; Lenders MM; Kühl K; Reinhardt L; André F; Dudda M; Ring N; Ebel C; Stäger R; Zellweger C; Lang R; Paar M; Gussek P; Richtig G; Stürmer SH; Kimeswenger S; Oellinger A; Forschner A; Leiter U; Weide B; Gassenmaier M; Schraag A; Klumpp B; Hoetzenecker W; Berking C; Richtig E; Ziemer M; Mangana J; Terheyden P; Loquai C; Nguyen VA; Gebhardt C; Meier F; Diem S; Cozzio A; Flatz L; Röcken M; Garbe C; Eigentler TK
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986126
[TBL] [Abstract][Full Text] [Related]
4. Granzymes expression patterns predict immunotherapy response and identify the heterogeneity of CD8+ T cell subsets.
Li J; Zhang H; Wu J; Li L; Xu B; Song Q
Cancer Biomark; 2023; 38(1):77-102. PubMed ID: 37545222
[TBL] [Abstract][Full Text] [Related]
5. Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort.
Bai X; Kim M; Kasumova G; Si L; Tang B; Cui C; Yang X; Wei X; Cohen J; Lawrence D; Freedman C; Fadden R; Rubin K; Sharova T; Frederick D; Flaherty K; Sullivan R; Guo J; Boland G
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33632901
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of an immune gene set-based prognostic signature in cutaneous melanoma.
Tian Q; Gao H; Zhao W; Zhou Y; Yang J
Future Oncol; 2021 Nov; 17(31):4115-4129. PubMed ID: 34291650
[TBL] [Abstract][Full Text] [Related]
7. uPAR
Porcelli L; Guida M; De Summa S; Di Fonte R; De Risi I; Garofoli M; Caputo M; Negri A; Strippoli S; Serratì S; Azzariti A
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33972390
[TBL] [Abstract][Full Text] [Related]
8. Development of an IFNγ response-related signature for predicting the survival of cutaneous melanoma.
Hu B; Wei Q; Li X; Ju M; Wang L; Zhou C; Chen L; Li Z; Wei M; He M; Zhao L
Cancer Med; 2020 Nov; 9(21):8186-8201. PubMed ID: 32902917
[TBL] [Abstract][Full Text] [Related]
9. A novel prognostic biomarker LCP2 correlates with metastatic melanoma-infiltrating CD8
Wang Z; Peng M
Sci Rep; 2021 Apr; 11(1):9164. PubMed ID: 33911146
[TBL] [Abstract][Full Text] [Related]
10. Major pathologic response on biopsy (MPRbx) in patients with advanced melanoma treated with anti-PD-1: evidence for an early, on-therapy biomarker of response.
Stein JE; Soni A; Danilova L; Cottrell TR; Gajewski TF; Hodi FS; Bhatia S; Urba WJ; Sharfman WH; Wind-Rotolo M; Edwards R; Lipson EJ; Taube JM
Ann Oncol; 2019 Apr; 30(4):589-596. PubMed ID: 30689736
[TBL] [Abstract][Full Text] [Related]
11. PMEL as a Prognostic Biomarker and Negatively Associated With Immune Infiltration in Skin Cutaneous Melanoma (SKCM).
Zhang S; Chen K; Liu H; Jing C; Zhang X; Qu C; Yu S
J Immunother; 2021 Jul-Aug 01; 44(6):214-223. PubMed ID: 34028390
[TBL] [Abstract][Full Text] [Related]
12. Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma.
Jiang J; Ding Y; Wu M; Chen Y; Lyu X; Lu J; Wang H; Teng L
Cancer Med; 2020 Nov; 9(22):8498-8518. PubMed ID: 32969604
[TBL] [Abstract][Full Text] [Related]
13. Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients.
Subrahmanyam PB; Dong Z; Gusenleitner D; Giobbie-Hurder A; Severgnini M; Zhou J; Manos M; Eastman LM; Maecker HT; Hodi FS
J Immunother Cancer; 2018 Mar; 6(1):18. PubMed ID: 29510697
[TBL] [Abstract][Full Text] [Related]
14. 9-Gene Signature Correlated With CD8
Yan K; Lu Y; Yan Z; Wang Y
Front Immunol; 2021; 12():622563. PubMed ID: 34220795
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas.
Shoushtari AN; Chatila WK; Arora A; Sanchez-Vega F; Kantheti HS; Rojas Zamalloa JA; Krieger P; Callahan MK; Betof Warner A; Postow MA; Momtaz P; Nair S; Ariyan CE; Barker CA; Brady MS; Coit DG; Rosen N; Chapman PB; Busam KJ; Solit DB; Panageas KS; Wolchok JD; Schultz N
Clin Cancer Res; 2021 Apr; 27(8):2226-2235. PubMed ID: 33509808
[TBL] [Abstract][Full Text] [Related]
16. Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Lepletier A; Madore J; O'Donnell JS; Johnston RL; Li XY; McDonald E; Ahern E; Kuchel A; Eastgate M; Pearson SA; Mallardo D; Ascierto PA; Massi D; Merelli B; Mandala M; Wilmott JS; Menzies AM; Leduc C; Stagg J; Routy B; Long GV; Scolyer RA; Bald T; Waddell N; Dougall WC; Teng MWL; Smyth MJ
Clin Cancer Res; 2020 Jul; 26(14):3671-3681. PubMed ID: 32345648
[TBL] [Abstract][Full Text] [Related]
17. Melanoma long non-coding RNA signature predicts prognostic survival and directs clinical risk-specific treatments.
Chen X; Guo W; Xu XJ; Su F; Wang Y; Zhang Y; Wang Q; Zhu L
J Dermatol Sci; 2017 Mar; 85(3):226-234. PubMed ID: 27955882
[TBL] [Abstract][Full Text] [Related]
18. In-depth plasma proteomics reveals increase in circulating PD-1 during anti-PD-1 immunotherapy in patients with metastatic cutaneous melanoma.
Babačić H; Lehtiö J; Pico de Coaña Y; Pernemalm M; Eriksson H
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32457125
[TBL] [Abstract][Full Text] [Related]
19. Association of NRAS Mutation With Clinical Outcomes of Anti-PD-1 Monotherapy in Advanced Melanoma: A Pooled Analysis of Four Asian Clinical Trials.
Zhou L; Wang X; Chi Z; Sheng X; Kong Y; Mao L; Lian B; Tang B; Yan X; Bai X; Li S; Guo J; Cui C; Si L
Front Immunol; 2021; 12():691032. PubMed ID: 34290710
[TBL] [Abstract][Full Text] [Related]
20. Landscape and Clinical Significance of Immune Checkpoint in Cutaneous Melanoma.
Mao R; Yang F; Zhang T; Li J
Front Immunol; 2021; 12():756282. PubMed ID: 35003069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
